2004, Número 3
<< Anterior
Ann Hepatol 2004; 3 (3)
Enlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma
Dietrich CG, Gartung C, Lorenzen J, Geier A, Wasmuth HE, Matern S, Lammert F
Idioma: Ingles.
Referencias bibliográficas: 11
Paginas: 118-120
Archivo PDF: 31.70 Kb.
FRAGMENTO
Sin resumen
REFERENCIAS (EN ESTE ARTÍCULO)
Chen HC, Chao YC, Shyu RY, Hsieh TY. Isolated tuberculous liver abscesses with multiple hyperechoic masses on ultrasound: a case report and review of the literature. Liver International 2003; 23: 346-50.
Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ. Hepatic granulomas: a 10 year single centre experience. Journal of Clinical Pathology 2003; 56: 850-3.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.[see comment]. American Journal of Respiratory & Critical Care Medicine 2003; 167: 1472-7.
Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antituberculotic medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-1079.
Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-30.
Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-9.
Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. Journal of Gastroenterology & Hepatology 2001; 16: 1033-7.
Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Safety 1996; 15: 394-405.
Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. Journal of Clinical Gastroenterology 1996; 22: 211-4.
Tahaoglu K, Atac G, Sevim T, Tarun T, Yazicioglu O, Horzum G, Gemci I, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. International Journal of Tuberculosis & Lung Disease 2001; 5: 65-9.
Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-48.